Scientists design new RNA therapy to bypass mutations behind thousands of genetic diseases

Scientists have developed a new RNA therapy that bypasses mutations responsible for thousands of genetic diseases. The therapy uses engineered transfer RNAs (tRNAs) and lipid nanoparticles to target nonsense mutations, as demonstrated in preclinical cystic fibrosis models. According to thebrighterside.news, the approach restores function of the CFTR protein, which is defective in cystic fibrosis.

Drug Target Review and BioWorld News both describe the therapy as a way to bypass nature’s full stop in genetic diseases. Cystic Fibrosis News Today adds that the therapy has shown promise in preclinical models of cystic fibrosis. The therapy is still in the preclinical stage.

The next steps will involve further testing and potentially moving into clinical trials. The success of this therapy in cystic fibrosis could pave the way for its application in other genetic diseases caused by nonsense mutations.